An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The company is set to start a phase 2/3 trial this month.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Global phase 2 data in TNBC look similar to earlier results in China.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
